NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS)

157 filings reported holding NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share as of Q4 2024.
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 98.6M shares of 114M outstanding shares and own 86.21% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (15.9M shares), Bain Capital Life Sciences Investors, LLC (10.7M shares), FCPM III SERVICES B.V. (10.6M shares), RA CAPITAL MANAGEMENT, L.P. (8.85M shares), VIKING GLOBAL INVESTORS LP (6.98M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (4.31M shares), JENNISON ASSOCIATES LLC (4M shares), Cormorant Asset Management, LP (3.25M shares), Medicxi Ventures Management (Jersey) Ltd (2.87M shares), and Woodline Partners LP (2.43M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.